Plaintiffs in the Yaz, Yasmin Mutli-District Litigation (MDL) in Federal Court have, through their attorneys, asked the federal judge overseeing the cases to allow submission of testimonial evidence showing that conflicts of interest influenced the FDA's regulatory decision to keep Yaz, Yasmin, Ocella, and other drosperinone-containing drugs on the market. It is anticipated that the defendant drug companies will attempt to introduce into evidence the findings of the FDA advisory panel in order to support their contention that the drug is safe.
In December, the FDA advisory panel voted 15-11 that the benefits of taking Yaz outweighed the risks of suffering life-threatening blood clots and gall baldder disease. It was subsequently reported that four members of the panel had previously received significant sums or money from Bayer and Barr Pharmaceuticals, the makers of Yaz.
Judge Herndon has not ruled on the evidentiary issue, and recently ordered the parties to meet with a mediator in order to attempt to settle the cases, however, if no settlement is forthcoming, the first MDL trials are anticipated to being in late April, 2012.
Dreyer Boyajian LLP is representing women who have suffered blood clots, pulmonary embolisms, DVT, and gall bladder disease as a consequence of taking Yaz, Yasmin, and Ocella. If you or a loved one has been injured, contact one of our products liability attorneys for a free consultation.